Sanofi, Glaxo covid vaccine works well in mid-stage study, shot on track
Volunteers showed a similar antibody response to people who have recovered from the coronavirus, the companies said in a statement Monday.17-05-2021
17-05-2021
Buy Sanofi India: target of Rs 9600: Sharekhan
Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9600 in its research report dated April 27, 2021.13-05-2021
Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed.06-05-2021
Sanofi India Ltd - 500674 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySanofi India Ltd 2CINL24239MH1956PLC009794 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: GIRISH TEKCHANDANI Designation: COMPANY SECRETARY EmailId: Girish.Tekchandani@sanofi.com Name of the Chief Financial Officer: VAIBHAV KARANDIKAR Designation: WHOLE TIME DIRECTOR AND CHIEF FINANCIAL OFFICER EmailId: Vaibhav.Karandikar@sanofi.com Date: 29/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.29-04-2021
Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are as enclosed29-04-2021
Sanofi India Ltd - 500674 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Sanofi India Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here28-04-2021
Sanofi India Ltd - 500674 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a summary of proceedings of the 65th Annual General Meeting of the Company held on 27th April 2021 through video conferencing facility. We are also enclosing a copy of the Scrutinizer's Report issued by M/s. Makarand M Joshi & Co., Company Secretaries on the remote e-voting conducted from 24th April 2021 to 26th April 2021 and e-voting at the Annual General Meeting held on 27th April 202128-04-2021
Sanofi India Q1 net profit rises to Rs 146 crore
Revenue from operations of the company stood at Rs 725.1 crore for the quarter under consideration. It was Rs 784.5 crore for the same period a year ago, Sanofi India said in a regulatory filing27-04-2021
Sanofi India Ltd - 500674 - Unaudited Financial Results For The Quarter Ended 31St March 2021
We refer to our letter dated 14th April 2021 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 12.00 noon and concluded at 1.45 p.m. The Board approved unaudited financial results for the quarter ended 31st March 2021. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter ended 31st March 2021 approved at this Meeting along with a copy of the Limited Review Report for your information.27-04-2021